It also reduces susceptibility to AF by inhibiting the activation of the PI3K-AKT and MEK1/2-ERK1/2 signaling pathways, thereby suppressing Ang II-induced atrial fibrosis and AF progression (Wang et al., 2022). The gene discussed is MAP2K1; the disease is atrial fibrillation.